Ziihera, a therapeutic antibody developed using ProBioGen's proprietary GlymaxX technology, has become commercially available ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an investigation under section 232 of the ...

Alliance Global Partners analyst James Molloy lowered the firm’s price target on Can-Fite BioPharma (CANF) to $4.50 from $12 and keeps a Buy ...

Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a ...

Can-Fite BioPharma (CANF) announced that it has entered into definitive agreements for the purchase and sale of 2.5M of the company’s American ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Despite President Donald Trump’s threat last week that tariffs on pharmaceuticals will come “very shortly,” the biopharma ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...

Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now dueTORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ...